Abstract
Thromboembolic complications in patients with atrial fibrillation (AF) are one of the leading problems in everyday clinical practice. The appropriate prophylaxis allows not only to reduce the incidence of ischemic strokes, but also to reduce mortality in this group of patients. New non-vitamin K antagonist oral anticoagulants, due to their high efficiency and favourable safety profile, are currently the standard of therapy in patients with AF and high thromboembolic risk. The choice of anticoagulant and its dose are based on the individual needs of the patient, adjusted to the renal function, the risk of bleeding, as well as the age and weight.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
